Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in FTH held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 2.0M | $50.5M | +5747.1% | 7.818% | 0.92% |
| 2 | Avoro Capital Advisors LLC | 1.4M | $36.1M | β | 5.588% | 0.32% |
| 3 | BAKER BROS. ADVISORS LP | 1.3M | $32.2M | β | 4.978% | 0.16% |
| 4 | BALYASNY ASSET MANAGEMENT L.P. | 1.0M | $26.1M | +6331.3% | 4.033% | 0.03% |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 722K | $18.1M | β | 2.794% | 0.16% |
| 6 | Vivo Capital, LLC | 722K | $18.1M | 0.0% | 2.794% | 1.65% |
| 7 | Logos Global Management LP | 722K | $18.1M | +2306.7% | 2.794% | 0.78% |
| 8 | Fairmount Funds Management LLC | 722K | $18.1M | β | 2.794% | 1.19% |
| 9 | Caligan Partners LP | 629K | $15.7M | +399.6% | 2.436% | 0.74% |
| 10 | B Group, Inc. | 610K | $15.3M | β | 2.361% | 7.16% |
| 11 | Trails Edge Capital Partners, LP | 515K | $12.9M | +312.3% | 1.994% | 2.05% |
| 12 | FRANKLIN TEMPLETON INC | 495K | $12.4M | +270.4% | 1.914% | 0.00% |
| 13 | Octagon Capital Advisors LP | 361K | $9.0M | β | 1.397% | 0.81% |
| 14 | ADAR1 Capital Management, LLC | 361K | $9.0M | β | 1.397% | 0.41% |
| 15 | Cormorant Asset Management, LP | 1.0M | $7.7M | +235.8% | 3.979% | 0.39% |
| 16 | MARSHALL WACE, LLP | 207K | $5.2M | +214.2% | 0.799% | 0.00% |
| 17 | Boxer Capital Management, LLC | 181K | $4.5M | β | 0.699% | 0.34% |
| 18 | Patient Square Capital LP | 175K | $4.4M | β | 0.677% | 0.68% |
| 19 | Alyeska Investment Group, L.P. | 144K | $3.6M | β | 0.559% | 0.01% |
| 20 | Affinity Asset Advisors, LLC | 144K | $3.6M | β | 0.559% | 0.16% |
| 21 | BOOTHBAY FUND MANAGEMENT, LLC | 134K | $3.3M | +411.6% | 0.517% | 0.04% |
| 22 | AWM Investment Company, Inc. | 111K | $2.8M | β | 0.431% | 0.24% |
| 23 | Richmond Investment Services, LLC | 80K | $2.0M | β | 0.308% | 0.63% |
| 24 | Ikarian Capital, LLC | 35K | $885K | +457.2% | 0.137% | 0.10% |
| 25 | UBS Group AG | 22K | $539K | +375.6% | 0.083% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in FTH β a direct measure of their conviction.
Filings activity in FTH during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 45 | +50% | 54.46% | +46.11 pp | $334M | +405% |
| Q1 2026 | 30 | +200% | 8.35% | +4.53 pp | $66M | +12749% |
| Q4 2025 | 10 | +11% | 3.82% | 0.09 pp | $1M | +10% |
| Q3 2025 | 9 | 25% | 3.91% | 2.94 pp | $0M | 23% |
| Q2 2025 | 12 | 43% | 6.85% | 0.34 pp | $1M | 20% |
| Q1 2025 | 21 | 13% | 7.19% | 1.52 pp | $1M | 34% |
| Q4 2024 | 24 | +20% | 8.71% | +0.49 pp | $1M | 13% |
| Q3 2024 | 20 | β | 8.22% | β | $1M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Latest Form 4 transactions by company officers and directors. Insider buys are widely viewed as a key fundamental indicator because executives are risking personal capital.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 24, 2026 | STEPHENSON BRIAN C | Buy | 3K | $25.22 | $73K |
| Jun 22, 2026 | STEPHENSON BRIAN C | Buy | 2K | $20.23 | $36K |
Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.
Quick answers to the most common questions about buying FTH stock.
Based on Q2 2026 13F filings, institutional ownership of Faeth Therapeutics, Inc. stands at 54.5%, held across 45 reporting institutions.
MONTANOVA CAPITAL, LLC is the largest reported institutional holder of FTH, with approximately 2,020,103 shares worth $0.05B as of Q2 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of FTH.
Our composite Smart Money Score for FTH is 56 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
22 institutions opened new positions in FTH during Q2 2026, while 6 fully exited. 16 added to existing positions and 7 trimmed.
FTH institutional ownership rose by 46.11 percentage points quarter-over-quarter, with a net change of +15 holders.
The top 10 institutions account for 74.3% of all reported 13F value in FTH, and the top 25 account for 98.8%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%), NXTS (3.3%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.